The Effect of AMH on Folliculogenesis
- PMID: 40408029
- DOI: 10.1007/s43032-025-01879-7
The Effect of AMH on Folliculogenesis
Abstract
Polycystic ovary syndrome (PCOS) is a common and frequent disease and always leads to endocrine and metabolic disorders among women of reproductive age. In most PCOS patients, the serum level of anti-mullerian hormone (AMH) is significantly higher than that of normal women of childbearing age. AMH is an important auxiliary diagnostic method for PCOS. AMH may play an important role in the occurrence and development of PCOS and potentially affect the success of in vitro fertilization (IVF) treatments, although the exact mechanisms remain unclear. This review focuses on the relationships and mechanisms of dysregulated AMH and follicular development in PCOS based on recent research. It is mainly manifested in the regulation of related signal pathways, the negative feedback regulatory loop of several gonadal hormones such as follicle-stimulating hormone, luteinizing hormone, estradiol, and testosterone, as well as the influence of AMH on IVF in PCOS patients. Additionally, it puts forward some suggestions, which will provide some helpful ideas or directions for future further research on PCOS.
Keywords: AMH; Folliculogenesis; Gonadal hormone; IVF; PCOS; Signal pathways.
© 2025. The Author(s), under exclusive licence to Society for Reproductive Investigation.
Conflict of interest statement
Declarations. Ethical Approval: This article is a review. It does not involve human or animal subjects and therefore does not require ethical approval. Consent to Participate: Not applicable. Consent for Publication: All authors fulfilled all conditions required for authorship and approved the submission of the manuscript. Conflicts of interest: The authors have no competing interests to declare that are relevant to the content of this article.
Similar articles
-
[Serum levels of anti-muller hormone in women with polycystic ovary syndrome and healthy women of reproductive age].Akush Ginekol (Sofiia). 2013;52 Suppl 1:16-23. Akush Ginekol (Sofiia). 2013. PMID: 24294740 Bulgarian.
-
The regulation and signalling of anti-Müllerian hormone in human granulosa cells: relevance to polycystic ovary syndrome.Hum Reprod. 2019 Dec 1;34(12):2467-2479. doi: 10.1093/humrep/dez214. Hum Reprod. 2019. PMID: 31735954
-
Serum anti-Müllerian hormone levels remain high until late reproductive age and decrease during metformin therapy in women with polycystic ovary syndrome.Hum Reprod. 2005 Jul;20(7):1820-6. doi: 10.1093/humrep/deh850. Epub 2005 Mar 31. Hum Reprod. 2005. PMID: 15802325
-
Anti-Müllerian hormone in PCOS: Molecular regulation and emerging therapeutic strategies.Biomol Biomed. 2025 Apr 15. doi: 10.17305/bb.2025.12070. Online ahead of print. Biomol Biomed. 2025. PMID: 40257231 Review.
-
Interactions between androgens, FSH, anti-Müllerian hormone and estradiol during folliculogenesis in the human normal and polycystic ovary.Hum Reprod Update. 2016 Nov;22(6):709-724. doi: 10.1093/humupd/dmw027. Epub 2016 Aug 27. Hum Reprod Update. 2016. PMID: 27566840 Review.
References
-
- Josso N. Professor Alfred Jost: the builder of modern sex differentiation. Sex Dev. 2008;2:55–63. - PubMed
-
- Cate RL, Mattaliano RJ, Hession C, Tizard R, Farber NM, Cheung A, et al. Isolation of the bovine and human genes for Mullerian inhibiting substance and expression of the human gene in animal cells. Cell. 1986;45:685–98. - PubMed
-
- Pepinsky RB, Sinclair LK, Chow EP, Mattaliano RJ, Manganaro TF, Donahoe PK, et al. Proteolytic processing of mullerian inhibiting substance produces a transforming growth factor-beta-like fragment. J Biol Chem. 1988;263:18961–4. - PubMed
-
- Wilson CA, di Clemente N, Ehrenfels C, Pepinsky RB, Josso N, Vigier B, et al. Mullerian inhibiting substance requires its N-terminal domain for maintenance of biological activity, a novel finding within the transforming growth factor-beta superfamily. Mol Endocrinol. 1993;7:247–57. - PubMed
Publication types
Grants and funding
LinkOut - more resources
Full Text Sources